Year 2023 / Volume 115 / Number 8
Original
Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study

444-449

DOI: 10.17235/reed.2022.9101/2022

María Dolores Martín Arranz, Laura García-Ramírez, Eduardo Martín Arranz, Dolores Montero Vega, José Luis Rueda García, María Sánchez-Azofra, Joaquín Poza Cordón, Jesús Noci Belda, Tamara Verges Martínez-Meco, Paula Blanco San Miguel, Cristina Suárez-Ferrer,

Abstract
Background and aims: response to the SARS-CoV-2 vaccine can be altered in patients with immune-mediated diseases, such as inflammatory bowel disease, and in patients under immunosuppressive treatment. The aims of this study were to evaluate the serologic response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease, to analyze the influence of immunosuppressive drugs on response, and to describe any adverse events in this population. Methods: this was a prospective study that included adult patients with inflammatory bowel disease. Baseline characteristics, concomitant treatments and previous COVID-19 symptoms were collected. Patients underwent serological testing before the first and after the second vaccine dose. Results: a total of 265 patients were consecutively included. Patients received one of the following vaccines: messenger RNA vaccines from Pfizer/BioNTech and Moderna; and adenovirus vaccines from AstraZeneca and Janssen. All adverse events were mild, and the most frequent was injection site pain in 141 (86 %) patients. The seroconversion rate according to the treatment that patients were receiving was: 100 % for those without treatment, 92.5 % for patients treated with mesalazine, 90.3 % for those receiving immunomodulators, 88.9 % for patients with biological monotherapy and 92.5 % for patients on combined treatment. The generation of antibodies according to the vaccine administered was: Pfizer 92.9 %, Moderna 93.3 %, AstraZeneca 98.4 %, and Janssen 12.5 %. Conclusion: the antibody response after vaccination against SARS-CoV-2 is high in patients with inflammatory bowel disease. However, patients treated with immunosuppressive or biologic drugs had a lower response. Adverse events were frequent, but not serious.
Share Button
New comment
Comments
No comments for this article
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Digestive Diseases Image

Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy

DOI: 10.17235/reed.2022.9218/2022

Digestive Diseases Image

Acute respiratory failure secondary to megaesophagus: think beyond COVID-19

DOI: 10.17235/reed.2022.8847/2022

Letter

COVID-19 vaccine and autoimmune hepatitis

DOI: 10.17235/reed.2022.8837/2022

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Letter

Surgical acute abdomen and COVID-19 vaccination

DOI: 10.17235/reed.2022.8721/2022

Letter

AMA-positive hepatitis induced by the SARS-CoV-2 vaccine.

DOI: 10.17235/reed.2022.8533/2021

Letter

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Letter

COVID-19 and aorto-enteric fistula

DOI: 10.17235/reed.2021.8272/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Letter

Pneumoperitoneum and COVID-19. A causal association?

DOI: 10.17235/reed.2021.7877/2021

Letter

COVID-19 and the liver: the chicken or the egg dilemma

DOI: 10.17235/reed.2021.7861/2021

Letter

Pancreatic injury and acute pancreatitis in COVID-19 patients

DOI: 10.17235/reed.2021.7807/2021

Editorial

Leading in turbulent times with the aim to serve

DOI: 10.17235/reed.2020.7684/2020

Letter

Pancreatic injury in COVID-19: pathogenesis and challenges

DOI: 10.17235/reed.2020.7541/2020

Letter

SARS-CoV-2 and acute pancreatitis: a new etiological agent?

DOI: 10.17235/reed.2020.7481/2020

Letter

Latin American authorship in scientific production on COVID-19

DOI: 10.17235/reed.2020.7432/2020

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Letter

COVID-19. Immunothrombosis and the gastrointestinal tract

DOI: 10.17235/reed.2020.7292/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Review

Anal Intraepithelial neoplasia: A narrative review

DOI: 10.17235/reed.2015.3788/2015

Citation tools
Martín Arranz M, García-Ramírez L, Martín Arranz E, Montero Vega D, Rueda García J, Sánchez-Azofra M, et all. Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study. 9101/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 576 visits.
This article has been downloaded 77 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 28/07/2022

Accepted: 15/12/2022

Online First: 16/01/2023

Published: 26/07/2023

Article revision time: 111 days

Article Online First time: 172 days

Article editing time: 363 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology